Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Mar 31, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Trials for the Month of March

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

10004: A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL). NCI Center for Cancer Research; Waldmann, Thomas Alexander. (301) 496-6656

 

9882: Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2’- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers. Rhode Island Hospital; Kinsella, Timothy James. (401) 444-6203

 

Phase II

AOST1521: A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Kopp, Lisa M. (520) 626-2021

 

Other Phases

AALL15B2-Q: Use of DNA Methylation Assessment by xMELP for Prognosis in Pediatric Patients with T-ALL. Children’s Oncology Group; Wertheim, Gerald. (267) 970-5918

 

AALL15B7-Q: Role of the MAPK/ERK Pathway in Relapsed Pediatric B-Lymphoblastic Leukemia: Prognostic Implications and Potential for Targeted Therapy. Children’s Oncology Group; Carroll, William L. (212) 263-9947

 

ANHL15B1-Q: B-Lineage Lymphoblastic Lymphoma SNP Array Profiling. Children’s Oncology Group; Miles, Rodney R. (801) 213-3448

 

AREN15B2-Q: Mapping Endogenous Mobile Elements in Rhabdoid Tumors. Children’s Oncology Group; Kentsis, Alex. (646) 888-2593

 

ARST15B2-Q: Validation of Anti-FGFR4 Antibodies as Potential Therapeutic Agents for Rhabdomyosarcoma. Children’s Oncology Group; Khan, Javed. (301) 439-2937

 

ARST15B4-Q: Infantile Rhabdomyosarcoma. Children’s Oncology Group; Arnold, Michael Andrew. (614) 722-5719

 

S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Pragmatic Traisl Assessing CSF Prescribing Effectiveness and Risk (TRACER). SWOG; Ramsey, Scott David. (206) 667-7846



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter